ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Endometrial Cancer
Ovarian Epithelial Carcinoma
Breast Cancer
Cancer
Fallopian Tube Cancer
Non-Small-Cell Lung Carcinoma
Triple Negative Breast Cancer

Ovarian Cancer trials near Charlotte, NC, USA:

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer (MAIA-ovarian)

The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in partici ...

Enrolling
Ovarian Cancer
Ovarian Cancer Recurrent
Drug: Normal Saline
Drug: COM701

Phase 1, Phase 2

Compugen

Charlotte, North Carolina, United States and 27 other locations

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objecti ...

Enrolling
Primary Peritoneal Cancer
Platinum-refractory Ovarian Cancer
Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin

Phase 3

Genelux

Charlotte, North Carolina, United States and 30 other locations

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Charlotte, North Carolina, United States and 176 other locations

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Charlotte, North Carolina, United States and 106 other locations

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular ...

Active, not recruiting
Ovarian Neoplasms
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Drug: Dostarlimab-Placebo
Drug: Standard of care

Phase 3

Tesaro
Tesaro

Charlotte, North Carolina, United States and 181 other locations

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian...

Enrolling
Ovarian Cancer
Drug: INCB123667
Drug: Investigator's choice of chemotherapy

Phase 3

Incyte
Incyte

Charlotte, North Carolina, United States and 167 other locations

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the s...

Enrolling
Primary Peritoneal Cancer
Epithelial Ovarian Cancer
Drug: Mirvetuximab Soravtansine
Drug: Bevacizumab

Phase 2

AbbVie
AbbVie

Charlotte, North Carolina, United States and 65 other locations

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian...

Enrolling
Endometrial Cancer
Platinum Resistant Ovarian Cancer
Drug: HWK-016, MUCIN-16-targeted ADC
Drug: Bevacizumab

Phase 1

Whitehawk Therapeutics, Inc.

Charlotte, North Carolina, United States and 11 other locations

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

PK, and PD of SON-DP in participants with relapsed/refractory/intolerant to standard of care therapies, for advanced/ metastatic solid tumors...

Enrolling
Solid Tumor
Breast Cancer
Drug: SON-DP

Phase 1

Qurgen

Huntersville, North Carolina, United States of America and 4 other locations

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors...

Enrolling
Other Solid Tumors
Breast Cancer
Biological: Autologous, engineered T Cells targeting TP53 R175H

Phase 1

AstraZeneca
AstraZeneca

Charlotte, North Carolina, United States and 17 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems